id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0279-0008,FDA,FDA-2014-E-0279,Notice of Final Determination Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T19:22:15Z,,0,0,090000648243b985
FDA-2014-E-0279-0007,FDA,FDA-2014-E-0279,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-01T04:00:00Z,2016,8,2016-08-01T04:00:00Z,,2016-08-02T01:36:42Z,,0,0,090000648214abfc
FDA-2014-E-0279-0006,FDA,FDA-2014-E-0279,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ELIQUIS",Notice,Determinations,2015-12-10T05:00:00Z,2015,12,2015-12-10T05:00:00Z,2016-02-09T04:59:59Z,2015-12-10T19:24:05Z,2015-31096,0,0,0900006481d9ab78
FDA-2014-E-0279-0005,FDA,FDA-2014-E-0279,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2015-11-18T05:00:00Z,2015,11,2015-11-18T05:00:00Z,,2015-11-18T14:38:23Z,,0,0,0900006481d50287
FDA-2014-E-0279-0004,FDA,FDA-2014-E-0279,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-03-25T04:00:00Z,2015,3,2015-03-25T04:00:00Z,,2015-03-25T15:19:03Z,,0,0,0900006481a63ea8
FDA-2014-E-0279-0003,FDA,FDA-2014-E-0279,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-03-27T04:00:00Z,2014,3,2014-03-27T04:00:00Z,,2014-03-27T14:58:30Z,,0,0,0900006481686bb3
FDA-2014-E-0279-0001,FDA,FDA-2014-E-0279,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2014-03-06T05:00:00Z,2014,3,2014-03-06T05:00:00Z,,2014-03-06T15:04:36Z,,0,0,0900006481605dc8
FDA-2014-E-0279-0002,FDA,FDA-2014-E-0279,"Patent Extension from Fitzpatrick, Cella, Harper & Scinto (Bristol-Myers Squibb Company)",Other,Application,2014-03-06T05:00:00Z,2014,3,2014-03-06T05:00:00Z,,2014-03-06T15:04:57Z,,0,0,0900006481605dc7